Skip to main content

Table 1 Clinical information of AMD patients

From: Complement component C5a Promotes Expression of IL-22 and IL-17 from Human T cells and its Implication in Age-related Macular Degeneration

PT number Race, Age, Gender Type of Disease CFH rs1061170 C2/CFB
Rs933739
C3
Rs2230199
Ocular therapy+ Co-Morbidities* Medications++
1 W, 94, F Wet OU TC GG CC anti-VEGF, PDT 19 H
2 W, 80, F Wet OU TT GG CC anti-VEGF, PDT 8 W, L, X
3 W, 97, F Wet OU TC GG CC anti-VEGF, Isteroids none W
4 W, 92, F Wet OU TC GG CC anti-VEGF 14, 16, 21 Z, G, O, BB
5 W, 91, M Wet OU TC GG CC anti-VEGF 2, 7, 18, 14 W, H, T, G, D, C, B
6 W, 91, M Wet OU TC GG CG anti-VEGF 10, 11, 14, 15 G, C, H, B, E
7 W, 83, F Wet OU CC GG CG anti-VEGF, PDT 8, 14, 16 W, Z, G
8 W, 79, F Wet OD, Dry OS CC GG CG anti-VEGF, Laser Rx 14, 15, 21 W, C, G, M, BB
9 W, 74, M Wet OU CC GG GG anti-VEGF, Laser Rx 7, 11, 14, 15 W, BB, E, Y, D, H, L, C, S
10 W, 77, M Wet OD, Dry OS TC GG CG anti-VEGF, Isteroids 14, 15 W, L, C, H, R
11 W, 74, M Dry OD, Wet OS TT GG CC anti-VEGF 3, 15, 16 W, Z, A
12 W, 82, F Wet OU TT GG GG anti-VEGF, PDT 10, 11 W, E, BB, L, F
13 W, 81, F Wet OU CC GG CG anti-VEGF, laser Rx 7, 14, 15 C, G, V
14 W, 75, M Wet OD, Dry OS TC GG CC None 14, 15, 23 C, G, H
15 W, 67, M Wet OD, Dry OS TC GG CC anti-VEGF, PDT 8, 15, 20 W, L, X, C, H, F
16 W, 72, F Wet OU TC GG CC anti-VEGF, Isteroids 12, 16 Z, I, G, W
17 W, 74, M Wet OU CC CG GG anti-VEGF, laser Rx, PDT 20 F, V
18 W, 77, F Wet OU CC - CC anti-VEGF, PDT, Isteroid 8 X
19 W, 75, M Dry OD, Wet OS CC GG CC anti-VEGF 11, 15 W, E, C, L
20 W, 82, M Wet OU - - - none 3, 5, 6, 7, 11, 19, P, B, G, A, E, D
21 W, 72, M Wet OU CC GG CG anti-VEGF, Isteroid 7, 14 H, G, D
22 W, 83, M Wet OD, Dry OS TC GG CC anti-VEGF, Isteroid 14, 15 W, L, H, G, C
23 W, 83, M Wet OD, Dry OS TT GG GG anti-VEGF, PDT 14, 15, 22 B, W, G, C,
24 W, 88, F Dry OD, Wet OS TC GG CC anti-VEGF 19 W, H,
25 W, 70, M Wet OD, Dry OS TC GG CC anti-VEGF 10 W
26 W, 83, F Wet OD, Dry OS TT GG CC anti-VEGF, Isteroids 8, 13, 14, 17, Q, G, Z, W
27 W, 80, M Dry OD, Wet OS CC GG CG anti-VEGF 7, 8, 14, 15, 21, 25 W, L, BB, Q, G, C, M, AA, D, BB
28 W, 95, M Dry OD, Wet OS TT CG CC anti-VEGF 1, 14, 15, 22 W, E, B, K, BB, C, G, T,
29 W, 79, F Wet OU CC GG CG anti-VEGF, PDT 7, 21, 24 W, L, D, V, CC, N
30 W, 84, M Wet OU TC GG CC PDT, Laser Rx 5, 8 G, H, C, X, A,
31 W, 80, M Wet OD, Dry OS CC CG CG anti-VEGF 4, 8, 15 W, BB, L, B, E, N, D, X
32 W, 97, F Wet OU - - - None 2 J, B
33 W, 77, M Wet OU TC GG CC anti-VEGF, Laser Rx 11 W, L, E
34 W, 57, M Wet OU, Wet OS TT GG CG anti-VEGF 3, 7, 14, 15, 26 A, C, D, G, BB, DD
35 W, 67, F Wet OU CT GG CG anti-VEGF 14, 15, 16, 21 G, M, Z, BB, EE
36 W, 82, F Wet OU CT CG CG anti-VEGF 7, 8, 14, 15, 16 C, G, K, Q, Z, BB
37 W, 84, F Wet OS CC GG CC anti-VEGF 15, 16 CC, L, G, Z,
38 W, 83, F Wet OU CT GG CG anti-VEGF 9, 14, 15, 28 B, C, BB
39 W, 84, F Wet OS TT GG CC anti-VEGF 16, 27 Z, CC
40 W, 90, F Wet OU CC GG CC anti-VEGF 27 B, G, H, O, BB, CC
  1. Ocular therapy+
  2. anti-VEGF- either Lucentis or Avastin intravitreal injections; Isteroids-Intravitreal steroid injections; PDT- Photodynamic
  3. therapy; Laser Rx- focal laser ablation of choroidal neovascularization
  4. Co-morbidities*
  5. 1. anemia; 2. atrial fibrillation; 3. benign prostatic hypertrophy; 4. cerebrovascular accident; 5. COPD; 6. coronary artery disease; 7. depression; 8. diabetes; 9. Colon Cancer; 10. Glaucoma; 11. GERD; 12. gout; 13. Hashimoto's thyroiditis; 14. hypertension; 15. hypercholesterolemia; 16. hypothyroid; 17. h/o low grade vitritis; 18. Lyme Disease; 19. myocardial infarction; 20. Ocular Hypertension; 21. osteoporosis; 22. pacemaker; 23. prostate cancer; 24. seasonal allergies 25. testicular failure; 26. Asthma; 27. Uterine cancer post hysterectomy and radiation 28: Breast cancer.
  6. Medications++
  7. A. Anti-Benign Prostatic Hypertrophy; B. Anti-Coagulants; C. Anti-Cholesterol; D. Anti-Depressants; E. Anti-GERD; F. Anti-Glaucoma drops; G. Anti-Hypertensive medication; H. Aspirin; I. Colchicine; J. Digoxin; K. Ferrous Fumarate; L. Fish Oil; M. Fosamax; N. Gapapentin; O. Glucosamine; P. Inhalers; Q. Insulin; R. Loratadine; S. Magnesium Citrate; T. Meclizine; U. Megestrol acetate; V. NSAIDs; W. Ocuvites; X. Oral Hypoglycemic agents; Y. Scopolamine; Z. Synthroid; AA. Testosterone injections; BB. Vitamins; CC. Premarin; DD. Singulair; EE. Calcitonin.